0000905718-22-000177.txt : 20220201
0000905718-22-000177.hdr.sgml : 20220201
20220201170039
ACCESSION NUMBER: 0000905718-22-000177
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220128
FILED AS OF DATE: 20220201
DATE AS OF CHANGE: 20220201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abingworth LLP
CENTRAL INDEX KEY: 0001397144
STATE OF INCORPORATION: X0
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 22579700
BUSINESS ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
BUSINESS PHONE: 44 (0)20 7534 1500
MAIL ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
sierraonco_fm4jan282022.xml
X0306
4
2022-01-28
0
0001290149
Sierra Oncology, Inc.
SRRA
0001397144
Abingworth LLP
PRINCES HOUSE 38 JERMYN STREET
LONDON
X0
SW1Y 6DN
UNITED KINGDOM
0
0
1
0
Common Stock, $0.001 par value
2022-01-28
4
X
0
287471
13.20
A
1164127
I
See footnote
Common Stock, $0.001 par value
2022-01-31
4
P
0
150000
27
A
1314127
I
See footnote
Series B Warrants (right to buy)
13.20
2022-01-28
4
X
0
287471
0
D
2020-01-22
Common Stock
287471
0
I
See footnote
The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.
/s/ John Heard, as attorney-in-fact
2022-02-01